Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Historic Non-Current Debt for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Q4 2024 value amounting to $331.6 million.

  • Syndax Pharmaceuticals' Non-Current Debt changed N/A to $331.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $331.6 million, marking a year-over-year change of. This contributed to the annual value of $331.6 million for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Non-Current Debt stood at $331.6 million for Q4 2024.
  • Syndax Pharmaceuticals' Non-Current Debt's 5-year high stood at $331.6 million during Q4 2024, with a 5-year trough of $11.0 million in Q3 2021.
  • In the last 4 years, Syndax Pharmaceuticals' Non-Current Debt had a median value of $17.8 million in 2020 and averaged $45.3 million.
  • The largest annual percentage gain for Syndax Pharmaceuticals' Non-Current Debt in the last 5 years was 1155.66% (2021), contrasted with its biggest fall of 4507.15% (2021).
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Non-Current Debt stood at $17.8 million in 2020, then increased by 11.56% to $19.9 million in 2021, then tumbled by 34.69% to $13.0 million in 2022, then soared by 2451.68% to $331.6 million in 2024.
  • Its last three reported values are $331.6 million in Q4 2024, $13.0 million for Q2 2022, and $16.5 million during Q1 2022.